Nutriband Sells 90% Stake in Pocono Pharmaceutical to EarthVision Bio for $5 Million

Reuters2025-12-29
Nutriband Sells 90% Stake in Pocono Pharmaceutical to EarthVision Bio for $5 Million

Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million USD. As part of the deal, Nutriband Inc. shareholders will retain a 10% shareholding in EarthVision Bio following the acquisition. The transaction is expected to close by December 31, 2025. Proceeds from the sale will be used by Nutriband Inc. to support the continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch. EarthVision Bio is focused on developing and commercializing sustainable product alternatives to plastic, molded fiber, wood, and paper, based on innovations by Dr. Gordon Moore and Dr. Hans Franke.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617606-en) on December 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment